Security88160RAB7 / Tesla Motors, Inc. Convertible Bond 0.250% Due 3/1/2019 (88160RAB7)
CEOMusk Elon
IndustryMotor Vehicles and Passenger Car Bodies
Institutional Owners50
Institutional Shares111,674,025 - 65.46%
Common Shares Outstanding170,593,144 shares (as of 2018-06-30)
Institutional Value$ 64,246,621,000 USD
Related TSLA / Tesla Motors, Inc.
88160RAC5 / Tesla Motors, Inc. Bond 1.25% Due 3/1/2021
88160RAD3 / Tesla Motors, Inc. Bond 2.375% Due 3/15/2022
88160RAA9 / Tesla Motors, Inc. Convertible Node 1.500% Due 6/1/2018

Institutional Bond Ownership and Shareholders

88160RAB7 / Tesla Motors, Inc. Convertible Bond 0.250% Due 3/1/2019 Institutional Ownership

Tesla Motors, Inc. Convertible Bond 0.250% Due 3/1/2019 (88160RAB7) has 50 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 111,674,025 shares. Largest shareholders include Capstone Investment Advisors, Llc, State Street Corp, Henderson Group Plc, Social Capital Pep Management Llc, Jane Street Group, Llc, Suntrust Banks Inc, Commonwealth Equity Services, Llc., MetLife Securities, Inc, and Natixis Asset Management.
Tesla Motors, Inc. Convertible Bond 0.250% Due 3/1/2019 (88160RAB7) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 21,828 22,039 0.97
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 6,833 2,894 -57.65
2018-08-14 13F-HR HBK INVESTMENTS L P 24,953 24,267 -2.75
2017-01-13 13F-HR MetLife Securities, Inc 10,000 10,000 0.00 9 9 0.00
2018-08-14 13F-HR Graham Capital Management, L.P. 85,250,000 85,039 114,815 35.01
2018-08-14 13F-HR Candriam Luxembourg S.C.A. 663
2018-08-07 13F-HR SSI INVESTMENT MANAGEMENT INC 9,915 10,760 8.52
2018-08-09 13F-HR BlackRock Inc. 1,869 1,433 -23.33
2018-07-23 13F-HR MIZUHO SECURITIES USA INC. 500,000 0 -100.00 497 0 -100.00
2018-08-14 13F-HR UBS Group AG 6 7 16.67
2018-08-15 13F-HR JANE STREET GROUP, LLC 250,000 278
2018-08-08 13F-HR 180 Wealth Advisors, Llc 12 12 0.00
2018-08-13 13F-HR LAZARD ASSET MANAGEMENT LLC 27,477 19,939 -27.43
2018-08-13 13F-HR CAPSTONE INVESTMENT ADVISORS, LLC 52,500,000 78,819,000 50.13 52,459 86,956 65.76
2018-08-14 13F-HR Man Group plc 11,476 23,126 101.52
2018-08-10 13F-HR Mint Tower Capital Management B.V. 1,103
2018-08-14 13F-HR LORD, ABBETT & CO. LLC 14,895 39,250 163.51
2018-08-14 13F-HR ROYAL BANK OF CANADA 18 20 11.11
2018-08-14 13F-HR DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 13,974 13,803 -1.22
2018-08-14 13F-HR SOROS FUND MANAGEMENT LLC 34,973 38,613 10.41
2018-08-14 13F-HR ADVENT CAPITAL MANAGEMENT /DE/ 22,641 24,391 7.73
2018-08-13 13F-HR Ferox Capital Management LP 18,487 17,225 -6.83
2017-02-10 13F-HR BlackRock Fund Advisors 66 46 -30.30
2018-08-14 13F-HR STIFEL FINANCIAL CORP 33,000 0 -100.00 33 0 -100.00
2018-08-13 13F-HR MML INVESTORS SERVICES, LLC 10,000 0 -100.00 997 0 -100.00
2018-08-13 13F-HR Mitsubishi UFJ Securities Holdings Co., Ltd. 230 166 -27.83
2018-08-14 13F-HR SUNTRUST BANKS INC 165,000 108,000 -34.55 164 118 -28.05
2018-08-14 13F-HR CREDIT SUISSE AG/ 9,469 2,204 -76.72
2018-07-27 13F-HR RWC Asset Management LLP 8,933 20,098 124.99
2018-08-14 13F-HR UBS OCONNOR LLC 63,316,000
2018-08-14 13F-HR TENOR CAPITAL MANAGEMENT Co., L.P. 31,955 35,925 12.42
2018-05-11 13F-HR CITIGROUP INC 1,911 323 -83.10
2018-08-10 13F-HR JD CAPITAL MANAGEMENT LLC 4,991 5,517 10.54
2018-08-14 13F-HR WHITEBOX ADVISORS LLC 28,407 28,101 -1.08
2018-07-31 13F-HR Commonwealth Equity Services, Llc. 16,000 16,000 0.00 15 18 20.00
2018-08-14 13F-HR Natixis Asset Management 1,025 1,025 0.00 1,022 1,136 11.15
2018-08-14 13F-HR Pomelo Capital LLC 9,992 9,115 -8.78
2018-08-13 13F-HR CAMDEN ASSET MANAGEMENT L P /CA 40,965 58,882 43.74
2018-08-17 13F-HR/A NOMURA HOLDINGS INC 0 0
2018-08-13 13F-HR Oz Management LP 41,788 23,603 -43.52
2017-08-14 13F-HR Fore Research & Management, LP 11,460
2018-07-18 13F-HR Castle Creek Arbitrage, LLC 7,728 7,436 -3.78
2018-08-14 13F-HR ARISTEIA CAPITAL LLC 43,631 72,995 67.30
2018-08-14 13F-HR HIGHBRIDGE CAPITAL MANAGEMENT LLC 21,694 28,958 33.48
2018-08-13 13F-HR Allianz Asset Management AG 95,990 91,070 -5.13
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 3,136 10,335 229.56
2018-08-09 13F-HR Fore Capital, Llc 14,976 17,800 18.86
2018-08-13 13F-HR Advisor Group, Inc. 3 3 0.00
2018-08-14 13F-HR STATE STREET CORP 28,554,000 29,679,000 3.94 28,376 32,865 15.82
2018-07-20 13F-HR Steward Partners Investment Advisory, Llc 4 6 50.00
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 10,939 18,723 71.16
2018-02-14 13F-HR GLG Partners LP 2,744 9,042 229.52
2018-08-10 13F-HR HENDERSON GROUP PLC 2,231,000 2,231,000 0.00 2,229 2,461 10.41
2018-08-14 13F-HR Social Capital Pep Management Llc 560,000 612

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 88160RAB7